home / stock / gnbt / gnbt news

GNBT News and Press, Generex Biotechnology From 04/14/20

Stock Information
Company Name: Generex Biotechnology
Stock Symbol: GNBT
Market: OTC
Website: generex.com
Menu
GNBT GNBT Quote GNBT Short GNBT News GNBT Articles GNBT Message Board
Get GNBT Alerts

News, Short Squeeze, Breakout and More Instantly...
GNBT - Generex Biotechnology Provides Update on the Development of an Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic

MIRAMAR, Fla., April 14, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) today announced that the company is working with corporate collaborators, academic advisors, and contract manufacturers, wi...
GNBT - Generex Biotechnology CEO Offers an Open Letter to Shareholders and Provides an Update on Corporate Response to the COVID-19 Pandemic

MIRAMAR, Fla., April 06, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) President & CEO Joseph Moscato offers an open letter to shareholders to provide an update on the company’s response,...

GNBT - Generex Biotechnology Subsidiary Olaregen Therapeutics' Wound Conforming Matrix, Excellagen®, Awarded Strategic Acquisition Centers (SAC) Biologic Blanket Purchase Agreement (BPA) Contract

The BPA contract facilitates the sales and distribution of Excellagen across the VA system’s 165 hospitals Excellagen wound conforming matrix is used to manage wounds including Diabetic Foot Ulcers, that affect a staggering 21% of our veterans MIRAMAR, Fla., March 30, 2020 (GLO...

GNBT - Generex Participating on Expert Panel for Fierce Pharma & Fierce Healthcare Corona Virus Virtual Series

MIRAMAR, Fla., March 30, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) announced that today Dr. Eric von Hofe, PhD, Chief Scientific Officer of NuGenerex Immuno-Oncology  (NGIO), a Generex ...
GNBT - Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for the Development of Effective Solutions to the SARS-CoV-2 Coronavirus Pandemic

Generex’s Ii-Key peptide vaccines for infectious disease and cancer have been studied in human clinical trials involving over 300 subjects in Phase I and Phase II clinical trials See publications at https://generex.com/covid-19 A Phase I clinical trial demonstrating the safe...

GNBT - Generex Subsidiary NuGenerex Immuno-Oncology (Formerly Antigen Express) Files Form 10 Registration Statement with the Securities and Exchange Commission

NuGenerex Immuno-Oncology (NGIO) is focused on modulation of the immune system to develop Ii-Key peptide vaccines for the treatment and prevention of cancer and infectious diseases NGIO advancing Ii-Key peptide vaccines into development with partners in the United States and China in an e...

GNBT - Generex Ii-Key Technology for Development of COVID-19 Vaccine Featured in Media

MIRAMAR, Fla., March 11, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT), and its subsidiary, NuGenerex Immune-Oncology (NGIO), have been featured in several news outlets and on a podcast regarding its Ii-Key vaccine platform and its development of a COVID-19 (corona...
GNBT - A Basket Of Biotechs

It is an exciting time in biotech. It seems like the big challenges are within reach. Cancer, diabetes, infectious diseases. Not everything, not right away. There are still a lot of bald men, for example. And unfortunately, Alzheimer’s seems intractable. But for investors that can mea...

GNBT - Generex Biotechnology Subsidiary NuGenerex Immuno-Oncology Sponsors Susan G. Komen More Than Pink Walk

2020 Komen More Than Pink™ Walk Saturday March 14, 2020 in Orlando, Florida MIRAMAR, Fla., March 10, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that NuGenerex Immuno-Oncology is sponsoring the Susan G. Komen More than Pink Walk...

GNBT - Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines

-- Terms approved to proceed with collaborative effort with international consortium MIRAMAR, Fla., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) ( http://www.otcmarkets.com/stock/GNBT/quote ) today announced that the company has...
Previous 10 Next 10